Windward Bio Debuts on Nasdaq with 68% First-Day Surge
Clinical-stage biotechnology company Windward Bio (Nasdaq: WWB) successfully listed on the Nasdaq on November 13, 2026. The IPO was priced at $17.00 per share, but saw a significant first-day rally, closing at $28.50. This surge brings the company's market capitalization to approximately $1.69 billion. Windward Bio focuses on developing ultra-long-acting biologic therapies for chronic inflammatory diseases such as asthma, COPD, and atopic dermatitis. Its lead candidate, WIN378, is currently in Phase 2/3 clinical trials for severe uncontrolled asthma and Phase 2 trials for COPD. The company's pipeline also features WIN027, a bispecific antibody targeting TSLP and IL-13. The IPO marks the 11th successful listing for Qiming Venture Partners in 2026. Windward Bio was founded in 2024 and maintains strategic licensing agreements with Kelun-Biotech, Harbour BioMed, and Qyuns Therapeutics to support its global development efforts.
Topics: Biotechnology IPO Nasdaq Listing Venture Capital
Read the full article at PR Newswire
Part of the story Windward Bio Group Debuts on Nasdaq with $1.69 Billion Market Capitalization (2 articles)